Vivanza Biosciences Complete Financial Statements
In FY2025, Vivanza Biosciences (VIVANZA) reported revenue ₹55 Cr, net profit ₹1 Cr and EPS ₹0.14, with a net profit margin of 1.8% and ROE of 25.0%. Full financial statements from FY2016 to FY2025 (10 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Vivanza Biosciences share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VIVANZA Revenue, Net Profit & EBITDA — Year-on-Year Growth
VIVANZA YoY (Sept 2024 vs Sept 2025) — revenue +1733.3%, expenses +1733.3%.
VIVANZA Income Statement — Revenue, EBITDA & Net Profit
Vivanza Biosciences revenue ₹55 Cr, EBITDA ₹1 Cr, net profit ₹1 Cr, EPS ₹0.14 (2025) — net profit margin 1.8%. Explore VIVANZA true value to estimate fundamental worth using multiple valuation models.
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Jun 2016 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55 | 1 | 9 | 3 | 4 | 2 | 2 | 8 | 8 | 9 | 7 | 2 | 6 | 2 | 6 | 3 | 3 | 1 | 2 | 3 | 3 | 1 | 4 | 0 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 3 | 3 | 2 | 1 | 0 | 1 |
| Expenses | 55 | 1 | 9 | 3 | 5 | 2 | 1 | 7 | 8 | 9 | 6 | 1 | 6 | 2 | 5 | 3 | 3 | 0 | 2 | 2 | 3 | 1 | 4 | 0 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 2 | 3 | 2 | 1 | 0 | 1 |
| EBITDA | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit Margin % | 1.00% | -200.00% | 2.00% | 4.00% | -3.00% | 15.00% | 8.00% | 4.00% | 0.00% | 6.00% | 4.00% | -2.00% | -7.00% | 6.00% | 10.00% | 1.00% | -2.00% | -17.00% | 2.00% | 5.00% | -2.00% | -23.00% | 6.00% | -1900.00% | -3.00% | -17.00% | -3.00% | -14.00% | 12.00% | 18.00% | -200.00% | 19.00% | 5.00% | 5.00% | 9.00% | -19.00% | 0.00% | -42.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 0.14 | -0.25 | 0.02 | 0.00 | -0.10 | 0.07 | 0.01 | 0.07 | -0.26 | 0.12 | 0.05 | 0.42 | -0.50 | 0.19 | 1.15 | 0.65 | -0.32 | 0.80 | -0.12 | 0.52 | -0.19 | -0.42 | 0.41 | -0.76 | -0.38 | -0.54 | -0.41 | -0.31 | 0.11 | 0.25 | -0.66 | 0.05 | 0.32 | 0.15 | 0.20 | -0.38 | -0.56 | -0.78 |
VIVANZA Balance Sheet — Assets, Liabilities & Shareholders' Equity
VIVANZA total assets ₹17 Cr, total equity ₹4 Cr, total liabilities ₹17 Cr (2025) — ROE 25.0%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| Total Assets | 17 | 20 | 23 | 16 | 8 | 12 | 11 | 10 | 7 | 1 |
| Current Assets | 12 | 16 | 20 | 13 | 5 | 9 | 8 | 7 | 4 | 0 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 17 | 20 | 13 | 6 | 10 | 9 | 8 | 5 | 1 |
| LIABILITIES | ||||||||||
| Total Liabilities | 17 | 20 | 23 | 16 | 8 | 12 | 11 | 10 | 7 | 1 |
| Current Liabilities | 3 | 3 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 |
| Non-Current Liabilities | ||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||
| Total Equity | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 4 | 4 | 0 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 0 |
| Reserves & Surplus | 0 | 1 | 0 | -1 | -1 | -1 | -1 | 0 | -1 | 0 |
VIVANZA Cash Flow Statement — Operating, Investing & Financing
Vivanza Biosciences operating cash flow ₹-3 Cr, investing ₹0 Cr, financing ₹3 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -3 | 2 | -1 | 3 | -3 | 3 | 1 | 0 | -2 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Financing Activities | 3 | -2 | 1 | -3 | 3 | -3 | -1 | -1 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |